Cyclica and Arctoris are expanding their partnership to advance drug discovery programs for Alzheimer’s disease.
By combining Cyclica’s platform and capabilities with the biological assay development of Arctoris, the companies seek to advance research that will benefit patients suffering from Alzheimer’s and other neurogenerative diseases.
The planned expansion of the partnership follows the results of an initial engagement that yielded positive results for targets related to both oncology and neurodegenerative disease.
Dr. Martin-Immanuel Bittner, MD DPhil FRSA, CEO of Arctoris, is happy about the expanded partnership and says:
– (…) This is a highly synergistic partnership and I am excited about what we can achieve together for patients across the world.
For the full announcement, please visit Arctoris.
See more news